Xi et al. [88] proved that it reduced the microvessel count and microvessel density of the transplanted tumors in the BGC-823 cell bearing mice while Yang et al. [89] reported this drug had the advantage of decreasing VEGF-A, basic fibroblast growth factor (bFGF), vascular endothelial growth factor receptor 1 (VEGFR1), and mRNA expression levels of cyclin D1, c-myc, and c-fos in the BGC-823 tumor-bearing mice through suppressing the ERK/MAPK and the NF-κB pathway. Here, FLT1 is linked to neoplasm.